3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
52
Phase 1/2
21
Phase 1
15
Phase 3
14
Phase NA
2
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
18
Prostatic Neoplasms
16
Breast Neoplasms
11
Recurrence
8
Leukemia, Myeloid, Acute
8
Neoplasm Metastasis
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Colorectal Neoplasms
6
Ovarian Neoplasms
5
Myelodysplastic Syndromes
5
Multiple Myeloma
5
Melanoma
5
Leukemia
5
Head and Neck Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Lymphoma, Non-Hodgkin
4
Lung Neoplasms
4
Fatigue
4
Vomiting
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms, Castration-Resistant
3
Pain
3
Oropharyngeal Neoplasms
3
Nausea
3
Mesothelioma
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Liposarcoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Interventions
Rogaratinib
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Has results
×
Carcinoma, Transitional Cell
×
Clear all
NCT03410693
2022-09-28
FORT-1
Bayer
Phase 2/3
Completed
175 enrolled
19 charts